Pfizer Inc. (NYSE:PFE), which has been linked to a long list of other companies since giving up its pursuit of AstraZeneca (AZN), doesn't need to do a big deal to succeed, according to CEO Ian Read, reported Financial Times.
Their opinions in no way represent those of Barrons.com or Dow Jones & Company, Inc. Some of the reports' issuers have provided, or hope to provide, investment-banking or other services to the companies being analyzed.
The first step was the IPO of Pfizer's animal health business that gave rise to Zoetis (NYSE: ZTS ) in June 2013. That move cleared the way for the next step, namely reorganizing the company into three operational units: global innovative ...
Pfizer Inc. said Monday it would cut the price of its pneumococcal vaccine for the third time in three years as the pharmaceutical industry faces criticism over skyrocketing vaccine prices in developing markets.
Pfizer Inc. (NYSE:PFE) [Trend Analysis] reported that a strong U.S. dollar as well as current drug-patent losses contributed to a 52 percent decrease in net income in the Q4 and would depress results this year.
Pfizer Inc (NYSE:PFE) (TREND ANALYSIS) shares were traded near the 52-week high of $33.5. The stock closed last trading session at $32.45, with a volume of 25,975,881 shares against an average volume for the last 30 days of 26,098,314.